Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Sample Testing

Analytics Overview

48
Form 483s Issued
7
483s converted to WL
57
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
19 Nov 2024
Dr. Reddy's Laboratories Limited (Unit II)
Drugs
04 Oct 2024
Avenue Pharmacy Inc dba Pathway Pharmacy
Drugs
20 Sep 2024
Aarti Drugs Limited
Drugs
29 Aug 2024
Zydus Lifesciences Limited
Drugs
16 Aug 2024
Belcher Pharmaceuticals, LLC
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Christopher R Czajka
5
0
Taichun Qin
4
0
Justin A Boyd
4
1
Jessica P Mcalister
3
0
Adetutu M Gidado
2
2
TITLE/ COMPANY Issue Date Status Details
You have not established Laboratory controls that include the establishment of scientifically sound and appropriate specifications
Dr. Reddy's Laboratories Limited (Unit II)
19 Nov 2024 Normal Justification: Observation underscores issues in sample testing and labeling, impacting QC sample traceability.
Excerpt: Sample label does not include the source or location from where the sample was obtained.
View Details
Your firm released drug product in which the strength differs from, or its purity or quality falls below,
Avenue Pharmacy Inc dba Pathway Pharmacy
04 Oct 2024 Normal Justification: Testing errors directly led to potency failures, necessitating a focus on enhancing sample testing accuracy.
Excerpt: Your firm’s contract testing laboratory identified five potency failures...
View Details
You assign the storage conditions and retest or expiry dates of the APIs using test procedures that are not stability indicating.
Aarti Drugs Limited
20 Sep 2024 Normal Justification: Ensures reliability and robustness in testing results crucial for maintaining product quality.
Excerpt: Test procedures that are not stability indicating may lead to incorrect assessments of API quality.
View Details
Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products
Zydus Lifesciences Limited
29 Aug 2024 Normal Justification: Effective sample testing protocols are critical for accurate PPQ and ensuring intra- and inter-batch process consistency.
Excerpt: Statistical sampling plans were not adequately established or followed for PPQ evaluations.
View Details
Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.
Belcher Pharmaceuticals, LLC
16 Aug 2024 Normal Justification: Improper testing methods can lead to undetected microorganisms, endangering product sterility and consumer safety.
Excerpt: your firm's control testing lab utilizes the Sterility Testing Method (STM No. M109) which is inadequate...
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.